首页> 外文期刊>American Journal of Physiology >Casein kinase le and la as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8
【24h】

Casein kinase le and la as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8

机译:酪蛋白激酶Le和La作为多囊肾疾病和机械靶标的新型球员(R)-ROSCOVITINE和(S)-CR8

获取原文
获取原文并翻译 | 示例
           

摘要

Following the discovery of (R)-roscovitine's beneficial effects in three polycystic kidney disease (PKD) mouse models, cyclin-dependent kinases (CDKs) inhibitors have been investigated as potential treatments. We have used various affinity chromatography approaches to identify the molecular targets of roscovitine and its more potent analog (S)-CR8 in human and murine polycystic kidneys. These methods revealed casein kinases 1 (CK1) as additional targets of the two drugs. CKle expression at the mRNA and protein levels is enhanced in polycystic kidneys of 11 different PKD mouse models as well as in human polycystic kidneys. A shift in the pattern of CKla isoforms is observed in all PKD mouse models. Furthermore, the catalytic activities of both CKle and CKla are increased in mouse polycystic kidneys. Inhibition of CKle and CKla may thus contribute to the long-lasting attenuating effects of roscovitine and (S)-CR8 on cyst development. CDKs and CKls may constitute a dual therapeutic target to develop kinase inhibitory PKD drug candidates.
机译:在发现(R)-Roscovitine在三种多囊肾疾病(PKD)小鼠模型中的有益效果之后,已经研究了细胞周期蛋白依赖性激酶(CDK)抑制剂作为潜在治疗。我们使用了各种亲和层析方法来鉴定Roscovitine的分子靶标及其在人和鼠多囊肾脏中的富有效率的模拟(S)-Cr8。这些方法揭示了酪蛋白激酶1(CK1)作为两种药物的额外靶标。 mRNA和蛋白质水平的CKLE表达在11种不同的PKD小鼠模型以及人的多囊肾脏中的多囊肾中增强。在所有PKD小鼠模型中观察到CKLA同种型模式的转变。此外,小鼠多囊肾脏的CKLE和CKLA的催化活性增加。因此,CKLE和CKLA的抑制可以有助于Roscovitine和(S)-Cr8对囊肿发育的长期衰减作用。 CDK和CKLS可以构成一种开发激酶抑制性PKD药物候选者的双重治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号